STOCK TITAN
  1. Home
  2. News
  3. RYTM

Rhythm Pharmaceuticals Inc. - RYTM STOCK NEWS

IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
conferences earnings
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
IMPACT
SENTIMENT
RYTM : Nasdaq
NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
clinical trial
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million
IMPACT
SENTIMENT
RYTM : Nasdaq
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
fda approval
Stock RYTM logo
Rhythm Pharmaceuticals Inc.

Nasdaq:RYTM

RYTM Rankings

#2292 Ranked by Market Cap
#2878 Ranked by Stock Gains
N/A Ranked by Dividends

RYTM Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About RYTM

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.